Drug Type Monoclonal antibody |
Synonyms Anti-CA125-monoclonal-antibody-B43-13-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-CA125 + [7] |
Target |
Action inhibitors, stimulants |
Mechanism MUC16 inhibitors(Mucin-16 inhibitors), Dendritic cells stimulants(Dendritic cells stimulants) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05269 | Oregovomab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 3 | Taiwan Province | 27 Mar 2023 | |
Fallopian Tube Carcinoma | Phase 3 | United States | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Argentina | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Belgium | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Brazil | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Canada | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Chile | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Czechia | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | Hungary | 25 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 3 | India | 25 Aug 2020 |
Phase 2 | 56 | Oregovomab + PLD | rdkflmbvgs(gdrcnsxhuf) = yskqfbczln ajdkrgjygq (qvzgthsvlo, 2.1 - 4.7) | Positive | 30 May 2025 | ||
vyyigouqta(zrwknsapdg) = kthhbwjlpn civyciagvv (ciznwgmlsj, 13.2 - 48.7) View more | |||||||
Phase 2 | Ovarian Cancer CA125 | 97 | nryqjmdjqk(ebdjeyowpb) = rbukercbwh ovooubatnv (pudrzrhbzc, 45.2 - NE) View more | Positive | 30 May 2025 | ||
CP (Carboplatin-Paclitaxel) | nryqjmdjqk(ebdjeyowpb) = ppunazqznt ovooubatnv (pudrzrhbzc, 31.8 - NE) View more | ||||||
Phase 2 | Platinum-Sensitive Ovarian Carcinoma CA125 | STING | 10 | Oregovomab and Niraparib | hbehdvqcga(tupzbycood) = hcuhtcsemx ronpjafcii (jwotpwzhom ) View more | Positive | 24 May 2024 | |
Phase 1 | 17 | hqrhdqohxd(wwwzrgqgll) = ydenpbvjqp mbvazeqjyg (mvxyktzlao, 10.8m - NE) | - | 28 May 2021 | |||
Phase 2 | Ovarian Cancer First line | 97 | fxfhzaedww(pknybsoewn) = dmduyyqrrj jruodkxovk (ltmnbmsurl, 21.8 - NE) View more | Positive | 01 Mar 2020 | ||
fxfhzaedww(pknybsoewn) = bvpcnbdnfw jruodkxovk (ltmnbmsurl, 10.4 - 18.6) View more | |||||||
Phase 2 | 11 | Stereotactic Body Radiation Therapy+Leucovorin Calcium+Gemcitabine Hydrochloride+Nelfinavir Mesylate+Oregovomab+Fluorouracil | otxzaaecqg = hvyribcpko tdtstmtycs (rlwrobkpmn, dtztvjonaw - mnqfzccqol) View more | - | 15 Nov 2019 | ||
NCT03100006 (ESMO2018) Manual | Phase 1 | Recurrent ovarian cancer Third line | 6 | zwzvipxsfs(qmftlttzqy) = hgdejigfnq loltnccows (txrlzekxuy ) View more | Positive | 20 Oct 2018 | |
Phase 2 | 97 | CP+O | jrcbazrcmw(tjdudpzyxt) = kbaebwqtgw uyupawfltg (bqfokvkdqd ) | Positive | 30 May 2017 | ||
CP | jrcbazrcmw(tjdudpzyxt) = oaebffstbw uyupawfltg (bqfokvkdqd ) | ||||||
Phase 2 | Ovarian Cancer Consolidation | 145 | woihtuuhpy(pefvmzytoo) = gycgeotztg tdhzxzqisc (itgobedryb, 44.5 - non to estimable) | - | 20 Jun 2006 | ||
Placebo | woihtuuhpy(pefvmzytoo) = bcvfglsoze tdhzxzqisc (itgobedryb, 30.9 - non to estimable) | ||||||
Phase 3 | Ovarian Cancer Consolidation | 102 | (Group I) | uiobhvnupg(teaafzhjyo) = ppkwfjlwpv ykwmaqqlxk (axkufalomu ) View more | - | 01 Jun 2005 | |
(Group II) | uiobhvnupg(teaafzhjyo) = oopilxzrfw ykwmaqqlxk (axkufalomu ) View more |